Intervention Protocol

You have free access to this content

Intravenous immunoglobulin to prevent relapses during pregnancy and postpartum in multiple sclerosis

  1. Nora Fernández Liguori1,*,
  2. Juan Ignacio Rojas2,
  3. Diana S Klajn3,
  4. Agustín Ciapponi4

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group

Published Online: 19 JUL 2013

DOI: 10.1002/14651858.CD010601


How to Cite

Fernández Liguori N, Rojas JI, Klajn DS, Ciapponi A. Intravenous immunoglobulin to prevent relapses during pregnancy and postpartum in multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD010601. DOI: 10.1002/14651858.CD010601.

Author Information

  1. 1

    Hospital Enrique Tornú, Multiple Sclerosis Clinic, Neurology Section, Buenos Aires, Argentina

  2. 2

    Hospital Italiano Buenos Aires, Neurology Department, Buenos Aires, Buenos Aires, Argentina

  3. 3

    Hospital Tornu, Academic and Research Department, Buenos Aires, Argentina

  4. 4

    Southern American Branch of the Iberoamerican Cochrane Centre, Argentine Cochrane Centre IECS, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Capital Federal, Argentina

*Nora Fernández Liguori, Multiple Sclerosis Clinic, Neurology Section, Hospital Enrique Tornú, Combatiente de Malvinas 3002, Buenos Aires, 1427, Argentina. nfliguori@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 19 JUL 2013

SEARCH

References

Additional references

Achiron 1996
  • Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth associated acute exacerbations in multiple sclerosis. A pilot study. Journal of Neurology 1996;243:25-8.
Achiron 2004
  • Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum related relapses in multiple sclerosis. Journal of Neurology 2004;251:1133-7.
Ansar 1985
  • Ansar Ahmed S, Penal WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. American Journal of Pathology 1985;121:531-51.
Ballow 2007
Beson 1994
Biogen Idec 2012
  • AVONEX® (interferon beta-1a) Intramuscular Injection. Prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103628s5189lbl.pdf 17 May 2013.
Confavreux 2008
  • Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. New England Journal of Medicine 1998;339:285-91.
Drew 2000
FDA 2003
  • U.S. Food, Drug Administration. Interferon beta-1b Product Approval Information - Licensing Action. 2003. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080486.htm (accessed 17 May 2013).
FDA 2006
  • U.S. Food, Drug Administration. FDA Approves Resumed Marketing of Tysabri Under a Special Distribution Program. 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108662.htm (accessed 17 May 2013).
FDA 2009
  • U.S. Food, Drug Administration. Interferon beta-1a Product Approval Information - Licensing Action. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080737.htm (accessed 17 May 2013).
FDA 2010
  • U.S. Food, Drug Administration. FDA approves first oral drug to reduce MS relapses. FDA News Release. 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm (accessed 17 May 2013).
FDA 2012
  • U.S. Food, Drug Administration. FDA approves new multiple sclerosis treatment Aubagio. FDA News Release. 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319277.htm (accessed 17 May 2013).
Feasby 2007
  • Feasby T, Banwell B, Benstead T, Bril V, Brouwers M, Freedman M, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfusion Medicine Reviews 2007;21(2 suppl 1):57-107.
Ferrero 2004
GRADEprofiler 2011
  • The GRADE Working Group. GRADEprofiler (GRADEpro). 3.6. The GRADE Working Group, 2011.
Haas 2007
Hartung 2002
  • Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
IFNB MS Study Group-UBC MS/MRI Analysis Group 1995
  • The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
Jacobs 1996
Johnson 1995
  • Johnson K, Brooks B, Cohen JA, Ford C, Goldstein J, Lisak R, et al. and the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-76.
Kappos 2010
  • Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine 2010;362:387-401.
Kim 1999
  • Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology 1999;52:1220-8.
Kurtzke 1983
Lublin 1996
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
McDonald 2001
Murray 2006
NMSS 2008
  • National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease Management Consensus Statement. http://www.nationalmssociety.org/download.aspx?id=8 (accessed 17 May 2013).
O'Connor 2011
  • O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine 2011;365:1293-303.
Orton 2006
Polman 2005
Polman 2006
  • Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 2006;354:899-910.
Polman 2011
Poser 1983
PRISMS Study Group 1998
  • PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
Review Manager 2013
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Rose 1993
TEVA 2009
  • COPAXONE (glatiramer acetate). Full prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020622s057lbl.pdf (accessed 17 May 2013).
Trisolini 2010
  • Trisolini M, Honeycutt A, Wiener J, Lesesne S. Global Economic Impact of Multiple Sclerosis. May 2010. http://www.msif.org/includes/documents/cm_docs/2011/g/global_economic_impact_of_ms.pdf?f=1 (accessed 17 May 2013).
Vickerrey 1995
Vukusic 2004
  • Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127;2004:1356-60.
Wegmann 1993
Weinshenker 1987
Whitaker 1998
WHO 2008
  • World Health Organization (WHO). Atlas: Multiple Sclerosis Resources in the World 2008. WHO and Multiple Sclerosis International Federation, 2008.